Tracking how a prostate cancer treatment works in everyday patients

This is a long-term observation study that follows men with metastatic castration-resistant prostate cancer who are being treated with lutetium (177Lu) vipivotide tetraxetan. Researchers want to understand how this treatment performs in everyday medical practice and how patients respond to it over time. The study will track participants for up to 18 months after they finish the medication.

This medication is already approved for treating advanced prostate cancer, but researchers need to learn more about how it works when used in regular clinical practice across different hospitals and clinics. By collecting real-world experience from many patients, doctors can better understand what outcomes to expect and how to help future patients.